Northeast Biotech Labs Are Leading a Quiet Digital Procurement Transformation

The stretch of highway between Boston and Philadelphia has long been the backbone of the American pharmaceutical and biotech industry. Kendall Square in Cambridge, the Route 128 corridor, the pharma belt running through central New Jersey, Connecticut’s growing biomedical cluster, and Philadelphia’s expanding life sciences district together form the densest concentration of drug development and biotech research talent in the country.

Now, companies across that corridor are grappling with a problem that has nothing to do with molecular biology or clinical trials — and everything to do with how they buy the reagents, pipette tips, cell culture media, and thousands of other supplies that keep their labs running.

The problem is procurement. And the fix is arriving faster than most people in the industry expected.

A System Built on Fax Machines and Phone Calls

For decades, lab procurement at biotech and pharmaceutical companies has operated like a relic from the 1990s. Researchers identify what they need, submit requests through internal systems that vary wildly in sophistication, and procurement teams spend hours chasing confirmations, comparing prices across dozens of vendor catalogs, and tracking shipments that may or may not arrive on schedule.

The numbers tell the story. According to a recent report from Entrepreneur UK, 67 percent of lab professionals say they would not recommend their current ordering process to a colleague. Nearly nine in ten — 89 percent — report experiencing delays caused by backorders. And procurement teams routinely spend more than 20 hours per week just on order confirmations and vendor follow-ups.

In an industry where Deloitte estimates the average cost to develop a single new drug has climbed to 2.3 billion dollars, those lost hours are not trivial. Every week a researcher spends tracking down a shipment of antibodies instead of running experiments is a week added to a development timeline that already stretches years.

“People outside this industry don’t realize how manual it still is,” said one procurement director at a mid-size New Jersey biotech who asked not to be named because she was not authorized to speak publicly. “We had scientists emailing PDF catalogs to each other. In 2026.”

New Jersey Feels the Pain Acutely

The Garden State has a particular stake in solving this problem. New Jersey is home to major operations for Merck, Johnson & Johnson, Bristol-Myers Squibb, Novo Nordisk, and dozens of smaller biotech firms clustered around the Route 1 corridor, the Princeton area, and the growing hub around New Brunswick.

These companies collectively employ tens of thousands of researchers and support staff, and they rely on supply chains that span thousands of vendors worldwide. When a lab in Rahway needs a specialized assay kit from a supplier in Germany, and another lab in Plainsboro needs the same kit from a different supplier at a different price, the inefficiency compounds quickly.

New Jersey’s pharmaceutical companies have historically managed procurement through a patchwork of enterprise resource planning systems, preferred vendor agreements, and — still, in many cases — manual processes involving spreadsheets and email chains. The state’s density of pharma operations means those inefficiencies are multiplied across hundreds of facilities.

The Digital Marketplace Model

The solution gaining traction across the Northeast corridor is a concept borrowed from consumer e-commerce: the digital marketplace. Rather than managing relationships with hundreds of individual vendors, labs can access a single platform that aggregates suppliers, standardizes pricing, and automates much of the ordering and tracking process.

Several companies are competing in this space. Quartzy offers lab management and ordering tools aimed at academic and smaller commercial labs. Labviva focuses on integrating with existing procurement systems at large enterprises. Scientist.com has built a marketplace for outsourced research services.

But the company drawing the most attention from Northeast biotech firms is ZAGENO, a Boston-headquartered platform founded in 2015 that has raised more than 88 million dollars in venture funding. ZAGENO’s procurement platform aggregates over 50 million SKUs from more than 6,000 suppliers into a single ordering interface — essentially turning lab procurement into something that looks more like Amazon than a filing cabinet full of vendor catalogs.

The platform’s proximity to the Northeast biotech corridor is not a coincidence. ZAGENO is headquartered in the same Cambridge ecosystem that produces many of its earliest customers, and its growth has tracked closely with the region’s biotech expansion.

What the Early Results Show

The most detailed public case study comes from Apogee Therapeutics, a Massachusetts-based biotech focused on immunology and inflammation. After adopting a digital procurement platform, Apogee consolidated purchasing across 98 separate vendors into a single system. The results in the first year were striking.

Purchase orders dropped by 40 percent. The company saved more than 200,000 dollars in staff time that had previously gone to manual procurement tasks. Its finance team recovered roughly 60,000 dollars in processing efficiencies. And researchers collectively gained back more than 250 hours that had been consumed by ordering and tracking supplies — hours that were redirected to actual research.

Those numbers matter in a sector where time-to-market can determine whether a drug reaches patients or gets shelved. When a company can recover 250 hours of research capacity without hiring a single additional scientist, the economics are hard to ignore.

Florian Wegener, ZAGENO’s chief executive, framed the shift in terms that resonate with the research community. “In science, every hour counts,” Wegener said. “The next generation of procurement technology is about giving researchers more time to push discovery forward and drive product cost savings.”

A Region Primed for the Shift

Industry analysts see the Northeast as the natural proving ground for this transformation. PwC has projected that 70 percent of life sciences procurement processes will be digitalized by 2027 — a target that seemed ambitious when it was first published but now looks increasingly achievable given the pace of adoption.

The region’s advantages go beyond just having a lot of biotech companies. The Northeast corridor also has the venture capital infrastructure — concentrated in Boston and New York — to fund the platforms that are driving the change. It has the talent pool, drawn from MIT, Harvard, Princeton, Penn, and Rutgers, to staff both the biotech firms and the technology companies serving them. And it has the density of operations that makes network effects possible: when one lab at a New Jersey pharma giant adopts a digital procurement platform and shares results internally, the pressure on neighboring facilities to follow suit builds quickly.

Connecticut’s biomedical sector, anchored by companies like Boehringer Ingelheim in Ridgefield and a growing cluster of smaller firms around New Haven, is also adopting digital procurement tools. Philadelphia’s life sciences corridor, which has expanded rapidly around the University of Pennsylvania and the Navy Yard district, represents another growth market.

What Comes Next

The shift is still in its early stages. Many large pharmaceutical companies in New Jersey and elsewhere operate under procurement contracts and ERP systems that were negotiated years ago and cannot be unwound overnight. Regulatory requirements around supplier qualification and traceability add complexity that does not exist in consumer e-commerce. And institutional inertia remains a powerful force in an industry that is, by necessity, cautious about changing established processes.

But the direction of travel is clear. The combination of rising drug development costs, intensifying competition for research talent, and proven results from early adopters is creating momentum that procurement teams across the Northeast are finding difficult to resist.

For New Jersey in particular, where pharmaceutical manufacturing and research have been economic pillars for more than a century, the procurement transformation represents something beyond just operational efficiency. It is a signal that the state’s life sciences sector is willing to modernize the infrastructure behind the science — not just the science itself.

The labs along the corridor from Cambridge to Philadelphia are not just developing the next generation of therapies. They are, quietly and methodically, rebuilding the systems that make that development possible. And in a region that has always prided itself on being where American pharma gets its work done, that matters.